Malcikova, J.
Tausch, E.
Rossi, D.
Sutton, L. A.
Soussi, T. http://orcid.org/0000-0001-8184-3293
Zenz, T.
Kater, A. P.
Niemann, C. U.
Gonzalez, D.
Davi, F.
Gonzalez Diaz, M.
Moreno, C.
Gaidano, G.
Stamatopoulos, K.
Rosenquist, R.
Stilgenbauer, S.
Ghia, P. http://orcid.org/0000-0003-3750-7342
Pospisilova, S.
,
Article History
Received: 1 September 2017
Revised: 5 December 2017
Accepted: 8 December 2017
First Online: 2 February 2018
Compliance with ethical standards
:
: JM and SP: consultancy fees and travel grants from Gilead and Abbvie. DR: research funding from Abbvie and Gilead, consultancy fees from Abbvie, Janssen, Gilead. LAS: honoraria for consultancy from Gilead and Janssen. TZ: honoraria from Janssen, Gilead, Abbvie, Vaniam Group, Roche. APK: research funding from Janssen, Gilead, Abbvie, Celgene, Roche. CN: research funding from Novo Nordisk Foundation, Danish Cancer Foundation and Abbvie and consultancy fees and/or travel grants from Roche, Janssen, Novartis, Gilead, and Abbvie. FD: consultant fees from Gilead. CM: consultant fees from Janssen, Gilead, Pharmacyclics and research funding from Roche and Gilead. GG: consultancy fees from Janssen, Gilead, Roche, Morphosys, and Abbvie. KS: research support from Janssen Pharmaceuticals, Gilead Sciences, Novartis SA, and Abbvie. RR: consultancy fees from Gilead and Roche. SS: honoraria for consultancy, honoraria and research grants from AbbVie, Celgene, Genentech, Gilead, GSK, Hoffmann La-Roche, Janssen, Novartis, Pharmacyclics. PG: honoraria for consultancy and research grants from AbbVie, Janssen, Gilead, Roche. The remaining authors declare that they have no conflict of interest.